Log in
Enquire now
‌

US Patent 10156559 Lipocalin fusion partners

Patent 10156559 was granted and assigned to Fred Hutchinson Cancer Research Center on December, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
0
Current Assignee
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
101565590
Patent Inventor Names
James Olson0
Christopher Mehlin0
Colin Correnti0
Roland Strong0
Date of Patent
December 18, 2018
0
Patent Application Number
146511750
Date Filed
December 10, 2013
0
Patent Citations Received
0
‌
US Patent 11919931 Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
0
Patent Primary Examiner
‌
Suzanne M Noakes
0
Patent abstract

Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10156559 Lipocalin fusion partners

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.